International Stem Cell Corp (ISCO)
0.0712
0.00 (0.00%)
USD |
OTCM |
Apr 17, 16:00
International Stem Cell Cash from Financing (TTM): 0.00 for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | 0.25M |
September 30, 2022 | 0.25M |
June 30, 2022 | 0.25M |
March 31, 2022 | 0.25M |
December 31, 2021 | 0.824M |
September 30, 2021 | 0.824M |
June 30, 2021 | 0.824M |
March 31, 2021 | 1.478M |
December 31, 2020 | 0.654M |
September 30, 2020 | 1.154M |
June 30, 2020 | 1.154M |
March 31, 2020 | 1.30M |
December 31, 2019 | |
September 30, 2019 | |
June 30, 2019 | |
March 31, 2019 | |
December 31, 2018 | 2.514M |
September 30, 2018 | 3.002M |
June 30, 2018 | 2.327M |
March 31, 2018 | 2.292M |
December 31, 2017 | 3.20M |
Date | Value |
---|---|
September 30, 2017 | 3.199M |
June 30, 2017 | 3.12M |
March 31, 2017 | 2.818M |
December 31, 2016 | 4.718M |
September 30, 2016 | 5.034M |
June 30, 2016 | 5.184M |
March 31, 2016 | 7.048M |
December 31, 2015 | 4.279M |
September 30, 2015 | 6.306M |
June 30, 2015 | 6.543M |
March 31, 2015 | 5.766M |
December 31, 2014 | 6.27M |
September 30, 2014 | 5.666M |
June 30, 2014 | 7.277M |
March 31, 2014 | 5.785M |
December 31, 2013 | 8.123M |
September 30, 2013 | 5.885M |
June 30, 2013 | 3.201M |
March 31, 2013 | 3.148M |
December 31, 2012 | 6.792M |
September 30, 2012 | 7.107M |
June 30, 2012 | 9.028M |
March 31, 2012 | 9.573M |
December 31, 2011 | 3.46M |
September 30, 2011 | 4.520M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
--
Minimum
Mar 2023
1.478M
Maximum
Mar 2021
0.5757M
Average
0.452M
Median
Cash from Financing (TTM) Benchmarks
AIM ImmunoTech Inc | 0.485M |
Perspective Therapeutics Inc | 0.785M |
Protalix BioTherapeutics Inc | 24.67M |
Electromed Inc | -0.128M |
Armata Pharmaceuticals Inc | 53.99M |